{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:12:53Z","timestamp":1788718373359,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic urothelial carcinoma (mUC) remains highly lethal despite advances in treatment. There is limited data surrounding the efficacy and toxicity of immune checkpoint inhibitors in treating elderly patients due to the high bar of clinical trial participation. The Geriatric 8 (G8) screening tool is a quick, 8-item questionnaire designed to assess frailty in older adults. This study evaluates the G8 tool\u2019s utility in predicting overall survival (OS) and progression-free survival (PFS) in patients with mUC treated with immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 48 mUC patients treated with ICI monotherapy at Winship Cancer Institute between 2016 and 2019. Baseline G8 scores were calculated from clinical notes. Primary outcomes included OS and PFS, analyzed using Kaplan-Meier, Cox proportional hazards models, and multivariate analysis adjusted for demographic and clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An impaired baseline G8 score predicted worse OS but not PFS. The incidence of immune-related adverse events was lower but not statistically significant in patients with impaired G8 scores (HR, 0.31; OR, 0.09-1.14; P\u2009=\u2009.077).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The G8 screening tool effectively predicts OS in older mUC patients treated with ICIs, highlighting its potential utility in clinical decision-making. Frail patients, as identified by the G8, had significantly worse survival outcomes, underscoring the need for tailored therapeutic approaches in this vulnerable population. Further studies are warranted to validate these findings and explore interventions that may improve outcomes for frail, older patients with mUC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf361","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:34:25Z","timestamp":1766406865000},"source":"Crossref","is-referenced-by-count":1,"title":["Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors"],"prefix":"10.1093","volume":"31","author":[{"given":"Christopher H","family":"Rhee","sequence":"first","affiliation":[{"name":"Medical College of Georgia, Augusta University\/University of Georgia Medical Partnership , Athens, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subir","family":"Goyal","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]},{"name":"Department of Biostatistics and Bioinformatics, Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-3058","authenticated-orcid":false,"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]},{"name":"Department of Biostatistics and Bioinformatics, Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan J","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M","family":"Shabto","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Nazha","sequence":"additional","affiliation":[{"name":"Piedmont Cancer Institute , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C","family":"Carthon","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-0906","authenticated-orcid":false,"given":"Jacqueline T","family":"Brown","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2026010223413429200_oyaf361-B1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010223413429200_oyaf361-B2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ageing\/afx166","article-title":"What is Comprehensive Geriatric Assessment (CGA)? An umbrella review","volume":"47","author":"Parker","year":"2018","journal-title":"Age Ageing"},{"key":"2026010223413429200_oyaf361-B3","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/jco.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026010223413429200_oyaf361-B4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.6004\/jnccn.2016.0146","article-title":"NCCN guidelines insights: older adult oncology, version 2.2016","volume":"14","author":"VanderWalde","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"2026010223413429200_oyaf361-B5","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/jco.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026010223413429200_oyaf361-B6","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"2026010223413429200_oyaf361-B7","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14030278","article-title":"Effectiveness and safety of immune checkpoint inhibitors in older cancer patients","volume":"14","author":"Vucinic","year":"2024","journal-title":"J Pers Med"},{"key":"2026010223413429200_oyaf361-B8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.7150\/jca.30723","article-title":"Aging, cancer and immunity","volume":"10","author":"Hong","year":"2019","journal-title":"J Cancer"},{"key":"2026010223413429200_oyaf361-B9","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010223413429200_oyaf361-B10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf361\/66125737\/oyaf361.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf361\/66125737\/oyaf361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf361\/66125737\/oyaf361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T04:41:39Z","timestamp":1767415299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf361\/8404450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf361","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,24]]},"article-number":"oyaf361"}}